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Abstract
The use of methamphetamine (MA) has increased in recent years, and is a major health concern throughout the world. The
use of MA has been associated with an increased risk of acquiring HIV-1, along with an increased probability of the
acquisition of various sexually transmitted infections. In order to determine the potential effects of MA exposure in the
context of an infectious agent, U937 macrophages were exposed to various combinations of MA and bacterial
lipopolysaccharide (LPS). Treatment with MA alone caused significant increases in the levels of TNF-a, while treatment with
both MA and LPS resulted in significant increases in TNF-a, IL-1b and the chemokine IL-8. The increases in cytokine or
chemokine levels seen when cells were treated with both LPS and MA were generally greater than those increases observed
when cells were treated with only LPS. Treatment with chemical inhibitors demonstrated that the signal transduction
pathways including NF-kB, MAPK, and PI3-Akt were involved in mediating the increased inflammatory response. As
discussed in the paper, these pathways appear to be utilized by both MA and LPS, in the induction of these inflammatory
mediators. Since these pathways are involved in the induction of inflammation in response to other pathogens, this
suggests that MA-exacerbated inflammation may be a common feature of infectious disease in MA abusers.
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Introduction
The abuse of methamphetamine (MA) is a major problem in
many parts of the world, including the United States of America,
Eastern Europe and Southeast Asia [1,2]. A recent study estimated
that over 10 million people, age 12 years and older, had tried MA
at least once in their lives [3]. The chemical similarity between
MA and the neurotransmitter dopamine appears to be the basis
for many of the effects of this drug [4,5].
Most studies on MA have focused on the effects of the drug in
the CNS where it has been shown to interact with dopamine
transporters (DAT) and dopamine receptors (D1-D5) (reviewed in
[6]). In the CNS, much of the MA-induced toxicity can be related
to changes in dopamine disposition as a result of altered expression
and activity of DAT and vesicular monoamine transporter-2 [6,7].
The neurotoxic effects of MA have also been shown to be
mediated through dopamine receptors. Antagonists of D1 and D2
have been shown to ameliorate the neuroxic effects of MA in the
CNS in animal models [8,9].
In the peripheral immune system, MA or dopamine have been
shown to affect peripheral blood mononuclear cells (PBMC),
macrophages and dendritic cells [10,11,12,13]. Exposure of mouse
bone marrow-derived dendritic cells to MA was demonstrated to
negatively impact antigen presentation and processing. MA caused
alkalization of endosomes and lysomes, and blocked antigen
presentation. Furthermore, treatment with MA inhibited phago-
cytosis by mouse bone marrow-derived macrophages [13].
Treatment of monocyte-derived dendritic cells with MA has been
demonstrated to result in increased expression levels of the
chemokine receptors CXCR4 and CCR5 [14]. Through the use of
D1 and D2 antagonists, it was demonstrated that both of these
dopamine receptors were involved in mediating the increase in the
chemokine receptors. Treatment of human monocyte-derived
macrophages with MA or dopamine was also shown to increase
infection of these cells with HIV-1, as well as to increase viral
replication; these effects were mediated by either D1 or D2
[10,11]. Similar results regarding HIV-1 infectivity in monocyte-
derived dendritic cells have also been reported [14]. Proteomic
analyses of PBMC isolated from HIV+ donors demonstrated that
MA treatment also altered the abundance of a number of proteins,
including several involved in mediating the effects of oxidative
stress. Compared to untreated PBMC, the levels of glutathione-S-
transferase, superoxide dismutase and peroxiredoxin 6 were
reduced in PBMC treated with MA [12]. Analysis of microarray
data obtained from MA-treated monocyte-derived dendritic cells,
followed by confirmation using real-time PCR, revealed that
exposure to MA resulted in increased expression of TNF-a, IL-1b,
and IL-8 [15].
In contrast to the effects of MA on macrophages, the molecular
aspects of LPS interactions with macrophages have been
extensively studied for more than 3 decades and numerous
reviews have covered relevant signal transduction pathways in
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with LPS binding protein which promotes the subsequent
interaction of LPS with CD14. LPS is then transferred to the
TLR4/MD2 complex which causes TLR4 to oligimerize, and this
results in the recruitment of TIR adaptor proteins (Mal, MyD88,
TRIF, TRAM and SARM). TLR4 signaling is then mediated
through the MyD88-dependent and MyD88-independent path-
ways, the former leading to the induction of inflammatory
cytokines while the latter leads to the induction of Type I
interferons. In the MyD88-dependent pathway, MyD88 recruits
the kinase IL-1 receptor-associated kinase 4 (IRAK4). IRAK-4
then activates another kinase of the same family, IRAK 1. IRAK 1
interacts with TRAF6 and together they activate TGF-b–activated
kinase 1 (TAK 1). TAK 1 then activates IKK of the NF-kB
pathway, and TAK 1 also activates the MAPK pathway. IKK
activation leads to the phosphorylation of inhibitor IkB which is
then degraded by the proteasome. This allows translocation of
active NF-kB to the nucleus where this transcription factor is
involved in the production of pro-inflammatory cytokines and
chemokines such as TNF-a, IL-8, and IL-1b. In contrast, the
MyD88-independent pathway leads to the activation of IRF3 and
the induction of Type I interferons. The MyD88-independent
pathway also leads NF-kB activation, but this occurs later than the
activation through the MyD88-dependent pathway.
Despite the prevalence of MA abuse, and the high coincidence
of bacterial infections among MA abusers, few studies have
attempted to determine the effects of MA on the production of
inflammatory cytokines in macrophages. One study using THP-1
macrophages found that treatment with only MA produced no
significant changes in IL-1b production, but MA did act to
increase IL-1b production stimulated by LPS [19]. In another
recent study using human monocyte-derived macrophages, the
effects of LPS and MA on secretion of matrix metalloproteinase-9
(MMP-9) were monitored. Although MA alone had no effect on
MMP-9 secretion, MA did significantly increase the level of MMP-
9 secretion induced by LPS [20].
The clinical relevance of potential MA-LPS interactions led us
to investigate the effects of chronic MA exposure on LPS-mediated
induction of inflammatory cytokines. To address this question we
utilized PMA-differentiated U-937 cells, as these are a well
established model of human macrophages. These cells were
treated for 48 h with MA and then exposed to LPS for three
hours. Expression levels of inflammatory cytokines were deter-
mined at both the mRNA and protein levels. Furthermore, to
enhance our understanding of MA-LPS interactions, the functions
of several signaling pathways in mediating these interactions were
determined.
Materials and Methods
Cell Culture and Treatment
The U937 monocytic cell line was obtained from ATCC
(Manassas, VA) and maintained in Roswell Park Memorial
Institute (RPMI) 1640 media (Sigma Aldrich, St. Louis, MO)
containing 10% FBS. U937 monocytes were differentiated into
macrophages by treatment with 100 nM phorbol 12-myristate 13-
acetate (PMA) for 48 h. The lipopolysaccharide (ReLPS) was
isolated from a deep rough mutant of Escherichia coli D31 m4
[21]. Cells were cultured with LPS (100 ng/ml), 500 mM
methamphetamine or LPS and MA at the times indicated in the
figure legends. In the experiments with inhibitors, the macro-
phages were cultured with either 20 mM SC-514 (IkB kinase
inhibitor), 10 mM SB203580 (p38 MAPK inhibitor), 10 mM
LY294002 (PI3K inhibitor) or 5 mM U-0126 (MEK1/2 inhibitor)
(Cayman Chemicals, Ann Arbor, Michigan) 1 h prior to the
addition of each dose of methamphetamine or LPS. After 3 h
stimulation with LPS, cells were harvested for RNA isolation. In
an additional experiment the cells were harvested after 24 h
incubation with the various combinations of MA and LPS for the
analysis of supernatant cytokines.
Real time RT-PCR and cytokine protein assays
Real time reverse transcriptase polymerase chain reaction (RT-
PCR) was used to determine the mRNA expression in a Bio-Rad
iCycler. Total RNA was extracted using an RNeasy kit (Qiagen,
Valencia, CA) as described in the manufacturer’s protocol. The
reaction conditions included reverse transcription at 50uC for
30 min, 95uC for 15 min and 45 cycles at 95uC for 15 sec and
62uC for 30 sec then at 74uC for 15 sec. Separate amplification of
hypoxanthine-guanine phosphoribosyl-transferase (HPRT) was
used to normalize gene expression. Fold-differences were calcu-
lated using the 2
2DDCT method [22].
The PCR probes and primers used were as follows: IL-8
forward primer 59 CTC TTG GCA GCC TTC CTG ATT 39,
reverse primer 59 TAT GCA CTG ACA TCT AAG TTC TTT
AGC A 39, and probe 59 FAM-CTT GGC AAA ACT GCA CCT
TCA CAC AGA-39 BHQ; IL-1b forward primer 59 -ACA GAT
GAA GTG CTC CTT CCA- 39 and reverse primer 59-GTC
GGA GAT TCG TAG CTG GAT- 39; TNF-a forward primer 59
-CCC AGG GAC CTC TCT CTA ATC- 39 and reverse primer
59-ATG GGC TAC AGG CTT GTC ACT- 39; HPRT forward
primer 59-GCT TTC CTT GGT CAG GCA GTA- 39 and
reverse primer 59 -CCA ACA CTT CGT GGR GTC CTT T- 39.
Cell culture supernatants were collected and the protein
concentrations of cytokines were analyzed by the Bio-Plex multi-
cytokine bead assay system (Life Science Research, Hercules, CA)
according to the manufacturer’s instructions. The protein
expression was measured using Bio-Plex Manager 5.0 software
and the fold changes were calculated by comparing the values with
the 5PL standard curve.
Western Blotting
U937 differentiated macrophages were harvested at the time
points indicated and nuclear and cytoplasmic extracts were
prepared using the NE-PER Nuclear extraction kit (Pierce,
Rockford, IL). Briefly, 20 mg of protein was loaded on a 10%
acrylamide gel and electrophoresed at 90 V for about 3 h and
transferred to a PVDF membrane at 350 mA for 90 min. The
expression of p50 was detected using NF-kB p50 (H-119) (1:1500)
primary antibody (Santa Cruz Biotechnology, Inc.). Lamin-B (C-
20) (1:1500) and GAPDH (FL-335) (1:2000) were used as
endogenous controls for the nuclear extracts and for the
cytoplasmic extracts respectively. HRP-conjugated secondary
antibodies were utilized to detect the primary antibodies and
proteins were visualized by BM Chemiluminescence Western
Blotting Substrate (POD) (Roche Applied Sciences, Indianapolis,
IN). Quantification was performed by spot densitometry using
FluorChem HD2 software (Alpha Innotech, San Leandro, CA).
Results
Methamphetamine augments the induction of
inflammatory cytokines by LPS
U937-differentiated macrophages were treated with bacterial
LPS and MA (individually as well as in combination) and then
cytokine expression was quantitated at the levels of mRNA and
protein. The concentration of MA (500 mM) was chosen because it
is midway between 240 and 1144 mM, the concentration range
Methamphetamine, LPS and Proinflammatory Cytokines
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[13]. The calculation is based on reports of serum concentrations
of MA and data regarding the serum/tissue ratio of MA in various
organs [23]. Treatment of U937 macrophages with MA and LPS
resulted in cytokine levels that were generally higher than those
observed when cells were treated with LPS alone. For IL-8,
treatment with MA resulted in IL-8 levels 2.560.2- fold higher
than control and LPS treatment resulted in levels 10.460.5-fold
higher than untreated controls at the RNA level, whereas
treatment with LPS in conjunction with MA resulted in IL-8
levels that were 24.361.3-fold higher than controls (Figure 1A).
For IL-8 expression at the protein level, MA treatment showed
only slightly higher levels than the untreated control, while LPS
produced significantly higher levels of IL-8 protein that were
further increased by concomitant treatment with LPS and MA
(Figure 1D). In the case of TNF-a, MA treatment resulted in RNA
levels that were approximately twice those of untreated cells, LPS
treatment resulted in levels 11.861.1- fold higher than controls,
whereas treatment with LPS in conjunction with MA resulted in
TNF-a levels that were 5764.8-fold higher than untreated
controls (Figure 1B). Increases in TNF-a at the protein level
paralleled the increases seen at the RNA level, but to a lesser
degree (17.6-fold difference in protein in cells treated with MA and
LPS compared to control) (Figure 1E). For IL-1b, MA treatment
resulted in RNA levels that were slightly higher than that of
control, while LPS and LPS +MA treatments resulted in cytokine
Figure 1. Treatment of U937 macrophages with MA or/and LPS induced an increase in IL-8, TNF-a, and IL-1b. Cells were differentiated
into macrophages by treatment with 100 nM PMA for 48 h. Cells were treated with MA at 0, 24 and 48 h and then stimulated with 100 ng/ml LPS for
3 h, after which they were harvested. RNA was isolated and analyzed with real-time RT-PCR (A–C). In a separate experiment, cells were treated with
MA at 0, 24 and 48 h then stimulated with 100 ng/ml LPS for 24 h and the cytokines in supernatants were measured using Bio-Plex (D–F). The error
bars show standard error of three independent experiments. *: p,0.05; **: p,0.01.
doi:10.1371/journal.pone.0033822.g001
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controls, respectively (Figure 1C). For IL-1b expression at the
protein level, MA and LPS produced an almost 2-fold increase in
cytokine level when used individually and an increase of almost 3-
fold when cells were treated with both agents at once (Figure 1F).
For all three cytokines/chemokine, IL-8, TNF-a, and IL-1b, the
levels of both RNA and protein induced by cotreatment with both
LPS and MA were significantly higher than the levels induced by
treatment with each agent alone.
LPS and MA cause an increase in NF-kB p50 in the
nucleus
The involvement of the NF-kB pathway in the regulation of the
expression of inflammatory cytokines has been well documented.
In order to gain some insight into the effects of MA and LPS on
NF-kB function, U937 macrophages were treated for 48 h with
500 mM MA, followed by exposure to LPS for 3 h. Cells were then
processed for the isolation of nuclear and cytoplasmic protein
fractions which were assayed for p50 expression by western blot
analysis (Figure 2). As expected, treatment with LPS resulted in a
significant increase in nuclear localization of p50 compared to that
of control. However, an increase in the nuclear/cytoplasmic ratio
of p50 for cells treated with MA alone was also observed. The
nuclear/cytoplasmic ratio of p50 for cells treated with only LPS
was not significantly different than the ratio for cells treated with
MA and LPS.
Cytokine induction mediated by a combination of LPS
and MA is abrogated by an inhibitor of NF-kB
Preincubation of U937 macrophages with an inhibitor of IKK2
of the NF-kB pathway, SC-514, resulted in significant inhibition of
TNF-a at the levels of both protein and mRNA (Fig. 3B and 3E).
Although pretreatment of U937 macrophages with SC-514 prior
to treatment with MA and LPS resulted in inhibition of IL-8 and
IL-1b in terms of both protein or RNA, the repression of cytokine
levels did not reach statistical significance (e.g. Fig. 3A, 3D, 3C,
and 3F). However, SC-514 did cause significant inhibition of IL-8,
TNF-a, and IL-1b protein and RNA levels that were induced by
treatment with both MA and LPS (Fig. 3A–F).
The MAPK and PI3-Akt pathways mediate the induction
of cytokines in macrophages stimulated with MA and LPS
In order to determine the role of signaling pathways in the
induction of inflammatory cytokines by MA and LPS, U937
macrophages were treated with inhibitors for p38 MAPK
(SB203580), ERK1/2 (U-0126), or PI3/Akt (LY294002) starting
at 1 h before each of the three daily treatments with MA.
Treatment with the ERK1/2 inhibitor inhibited the induction of
all cytokines by MA, LPS, or MA in combination with LPS
(Fig. 4A, 4B, and 4C). Treatment with the inhibitor of p38 MAPK
inhibited induction of TNF-a by MA, as well as the induction of
TNF-a and IL-8 by LPS or LPS/MA and the induction of IL-1b
by LPS/MA treatment (Fig. 4A, 4B and 4C). Treatment with the
inhibitor of PI3/Akt resulted in the inhibition of the induction of
IL-8 and IL-1b by MA, as well as the inhibition of the induction of
IL-8, IL-1b and TNF-a by LPS or LPS/MA (Fig. 4A, 4B, 4C).
Discussion
The induction of inflammation in macrophages by LPS has
been extensively studied for the past three decades. Although there
are still questions that remain to be resolved, it is clear that LPS/
TLR4 signaling involves the NF-kB, MAPK and PI3-Akt
pathways (reviewed in [16,17,18]). In contrast, very little is known
about the effects of MA on macrophages and the signaling
pathways that mediate these effects. Our results demonstrate that
LPS-treatment of macrophages exposed to MA for 48–72 h result
in the induction of IL-8, TNF-a and IL-1b to levels that were
greater than were seen by treatment of macrophages with LPS
alone. Although, as is to be expected, the actual fold-differences
were different for RNA and protein, the expression profiles
obtained at the level of RNA were virtually identical to the
expression patterns observed at the level of protein. At the level of
protein, MA alone induced significantly higher levels of TNF-a
and IL-1b. For all three cytokines/chemokines examined, the level
of protein induced by treatment with both MA and LPS was
significantly greater than the additive effects of each agent alone.
This suggests that, at least in some cases, MA and LPS may
interact synergistically to increase cytokine or chemokine produc-
Figure 2. Treatment of U937 macrophages with MA ± LPS resulted in increased translocation of the p50 subunit of NF-kB. 1610
6
U937 monocytes were differentiated into macrophages with 100 nM PMA for 48 h. Cells were treated with MA at 0, 24 and 48 h then stimulated with
100 ng/ml LPS for 3 h. Cytosolic and nuclear protein fractions were purified by electrophoresis on 10% SDS gel and transfer to a PVDF membrane.
The cytosolic fractions and nuclear fractions are shown in a representative western blot. The expression of the p50 subunit was normalized to the
appropriate compartmental housekeeping genes (Lamin B for nucleus and GAPDH for cytoplasm). The means and SE values are from three
independent experiments.
doi:10.1371/journal.pone.0033822.g002
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drugs of abuse on inflammation, particularly with respect to that
caused by infectious agents. Definitive proof of synergy requires
treatment with additional doses of these agents and these studies
are currently in progress. The induction of increased levels of IL-
1b by concomitant treatment with MA and LPS confirms a
Figure 3. An inhibitor of NF-kB abrogates cytokine/chemokine expression induced by MA ± LPS. (A–C)1610
6 U937 monocytes were
differentiated into macrophages with 100 nM PMA for 48 h. IKK2 inhibitor SC-514 was added 1 h before each MA exposure at 0, 24, 48 h. Cells were
treated with LPS and the final dose of MA and then harvested after 3 h for RNA isolation and real time RT-PCR analysis. The mRNA expression levels
were compared to untreated control. (D–F) For cytokine protein levels, cell supernatants were harvested 24 h after the last MA 6 LPS treatment. The
protein concentrations were normalized by subtracting values of control or inhibitor only. The means and SE values are from three independent
experiments. *:p,0.05; **: p,0.01 comparing to MA/LPS/LPS+MA treatment as positive controls.
doi:10.1371/journal.pone.0033822.g003
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production as measured by ELISA of cell culture supernatants
[19].
The results described above led us to inquire as to the
mechanisms responsible for the cytokine induction. LPS/TLR4
signaling pathways have been well described, but the signaling
pathways that mediate the effects of MA in macrophages remain
largely unexplored. However, it is known that macrophages
express D1 and D2 dopamine receptors. Through the use of
selective D1 or D2 inhibitors, it has been demonstrated that the
effects of MA in macrophages are mediated through either D1 or
D2 dopamine receptors [10,11]. Signaling through the D1 and D2
receptors has been demonstrated to be mediated through a
number of pathways, including the NF-kB pathway [24,25], the
MAPK pathways [24,26,27], and the PI3-Akt pathway
[28,29,30,31].
The first pathway we investigated was the NF-kB pathway.
Through the use of cytoplasmic and nuclear extracts, we
determined that treatment of U937 macrophages with MA for
48 h alters the nuclear:cytoplasmic ratio of the p50 subunit of NF-
kB. Cells treated with either LPS, or a combination of LPS and
MA showed an even greater effect in terms of the increase in p50
nuclear:cytoplasmic ratio. Although there was little difference
between the nuclear:cytoplasmic ratios observed between the cells
treated with LPS and those treated with both LPS and MA, we
postulate that this may be due to the ratio having reached its
maximum. The role of the NF-kB pathway in mediating the
induction of inflammatory cytokines in response to LPS and MA
was confirmed using SC-514, an inhibitor of IKK2. Although the
effects of SC-514 treatment on the induction of IL-8, TNF-a and
IL-1b by MA at the level of RNA were slight, the inhibitory effect
of SC-514 as shown by decreased cytokine production was more
apparent at the protein level. It is worthwhile to note that while
SC-514 inhibits IKK-2 (i.e. IKK-b), this kinase is thought to be
dispensable for LPS-mediated activation of NF-kB in macrophag-
es and monocyte-derived dendritic cells [32,33]. In our system the
activity of IKK-a (i.e. the non-canonical NF-kB pathway,
reviewed in [34]), or activation of cytokine production by an
alternative pathway (e.g. MAPK) may be the cause of the lack of
efficacy of SC-514 in inhibiting cytokine production in LPS-
stimulated macrophages. Furthermore, the effects of SC-514 were
statistically significant for all cytokines in terms of induction by
concomitant treatment with both LPS and MA, at both protein
and RNA levels. Taken together with the changes produced by the
different treatments on the nuclear-cytoplasmic distribution of
p50, this confirms that the NF-kB pathway is a key mediator of the
effects of MA on LPS-stimulated macrophages.
In addition to the NF-kB pathway, the MAPK signaling
pathway has also been demonstrated to mediate D1 and D2
signaling [24,26,27,35]. MA has been shown to affect phosphor-
ylation of ERK and p38 MAPK in macrophages [10] and
monocyte-derived dendritic cells [14]. We also determined the role
of the PI3-Akt pathway, as this pathway has also been shown to
modulate TLR4/LPS signaling [36] [37], as well as signaling
through D1 and D2 [28,29,30,31]. Our results demonstrated that
p38MAPK and ERK1/2 are involved in mediating MA-induction
of TNF-a. Our studies also show that MA-inductions of IL-8 and
IL-1b are mediated by the PI3-Akt pathway and ERK1/2.
Taken together with the results discussed above, it is important
to note that the use of any one of the signaling inhibitors, i.e.
inhibitors for p38 MAPK, PI3-Akt, ERK1/2, or NF-kB, results in
significant abrogation of MA-mediated increases of IL-8, IL-1b
and TNF-a. This is most probably because the pathways that
mediate MA-induced increases in these inflammatory cytokines
Figure 4. Inhibitors of MAPK or PI3-Akt abrogate cytokine/
chemokine expression induced by MA ± LPS. 1610
6 U937
monocytes were differentiated into macrophages by treatment with
100 nM PMA for 48 h. p38 inhibitor SB203580, PI3K/Akt inhibitor
LY294002 and ERK1/2 inhibitor U-0126 were added 1 h before MA
exposure at 0, 24, 48 h. Cells were then challenged with LPS and the
final dose of MA. After 3 h cells were harvested, RNA isolated and
analyzed by real time RT-PCR. The means and SE values are from three
independent experiments. *:p,0.05; **: p,0.01. Expression levels were
compared to the identical treatment without inhibitor.
doi:10.1371/journal.pone.0033822.g004
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We propose that it is through the utilization of these overlapping
pathways that MA exerts its effects on LPS-stimulated macro-
phages. Furthermore, as we have noted, while the use of an
inhibitor of IKK2 results in the inhibition of the LPS/MA
cotreatments, the ERK1/2 inhibitor abrogated cytokine induction
in response to the cotreatments with LPS and MA, as well as to the
treatments with LPS and MA individually. This may suggest that
ERK signaling is downstream of NF-kB signaling. A more
definitive analysis of the sequence of induction of these pathways
is currently in progress.
Although we have demonstrated that the NF-kB and MAPK
signaling pathways play key roles in the induction of inflammatory
cytokines by LPS and MA, the roles other signaling components
and pathways involved in this phenomenon remain to be
elucidated. For example, although dopamine receptors has been
shown to be expressed in macrophages (10, 11), direct binding of
MA to these receptors has not been demonstrated. In addition,
while we have demonstrated that the 2 major signaling pathways
in the induction of cytokines by LPS and MA, the effects of MA on
the upstream components of the TLR4 signaling pathway (e.g.
CD14, MyD88, TRAF6, etc.) have yet to be determined. It is quite
possible that MA affects LPS signaling by affecting the expression
or function of any of these components.
Our finding of the increased production of inflammatory
cytokines in response to MA also has important implications in
terms of the clinical effects of MA abuse. Numerous studies have
demonstrated a strong linkage between MA abuse and HIV
infection. MA abuse tends to increase risky sexual behaviors, and
is thus a contributing factor to the acquisition of HIV infection
[1,2]. In the early stages of HIV infection the virus enters the
CNS, most probably through trafficking of infected monocytes
across the blood-brain barrier (BBB). In a trend that has been
increasing in the past few years, the effects of HIV infection of the
CNS, a syndrome known as HIV-associated neurocognitive
disorder (HAND), have become more prevalent. Current thought
is that one of the major factors responsible for HAND is increased
neuroinflammation due to cytokine production induced by HIV-1
neurotoxins. A recent report has demonstrated that MA increases
levels of matrix metalloproteinase 9 (MMP9) in LPS-treated
macrophages [20]. Increased levels of this enzyme are associated
with increased trafficking of infected monocytes across the BBB
[38]. Taken together with our finding of MA-mediated induction
of increased levels of inflammatory cytokines, this suggests that
MA could operate on several levels to increase the prevalence of
HAND in HIV-infected abusers of the drug. Thus, MA may not
only increase the level of monocyte trafficking across the BBB, but
it may also act to increase the production of inflammatory
cytokines that are produced in microglia.
In summary, our results demonstrate that exposure to MA
increases the levels of the inflammatory cytokines IL-8, IL-1b and
TNF-a in LPS-treated macrophages. This is the first report that
has demonstrated the induction of inflammatory cytokines by MA
treatment of macrophages. The pathways that we have identified
as being involved in MA-mediated induction of these cytokines are
also key players in LPS-mediated inflammation. The exacerbation
of cytokine production in response to both agents is likely the result
of the utilization of overlapping signaling pathways activated by
MA and LPS. This finding has important implications because of
the potential of MA to exacerbate other inflammatory conditions
that also modulate the signaling pathways identified in this study.
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